FDA Formally Rescinds Laboratory-Developed Tests Final Rule

FDA Formally Rescinds Laboratory-Developed Tests Final Rule

The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.

The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.

Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.

Sources:

https://www.reginfo.gov/public/do/eoDetails?rrid=1044563

https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf

https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3

A logo with the letters 'HD' for 'HealthDay'

House E&C Subcommittee on Health Holds Another Hearing on Health Care Affordability

House E&C Subcommittee on Health Holds Another Hearing on Health Care Affordability

The House Committee on Energy and Commerce Subcommittee on Health held another hearing on June 10 in its affordability series to explore more...

Read More
TELCOR POC Device Connectivity Updates -2026 Q1

TELCOR POC Device Connectivity Updates -2026 Q1

Lincoln, NE - June 16, 2026 TELCOR QML® has connectivity for more than 160 device types. Whether you are looking to add new testing on devices...

Read More
TELCOR Brings New Operator Management Capabilities to ADLM 2026

TELCOR Brings New Operator Management Capabilities to ADLM 2026

Lincoln, NE – June 12, 2026 – TELCOR Inc, the industry leader in healthcare software for point of care testing and laboratory revenue cycle...

Read More